Literature DB >> 22991471

Heterogeneous nuclear ribonucleoprotein L-like (hnRNPLL) and elongation factor, RNA polymerase II, 2 (ELL2) are regulators of mRNA processing in plasma cells.

Micah J Benson1, Tarmo Aijö, Xing Chang, John Gagnon, Utz J Pape, Vivek Anantharaman, L Aravind, Juha-Pekka Pursiheimo, Shalini Oberdoerffer, X Shirley Liu, Riitta Lahesmaa, Harri Lähdesmäki, Anjana Rao.   

Abstract

B cells and plasma cells possess distinct RNA processing environments that respectively promote the expression of membrane-associated Ig by B cells versus the secretion of Ig by plasma cells. Through a combination of transcriptional profiling and screening using a lentiviral short-hairpin RNA interference library, we show that both the splicing factor hnRNPLL and the transcription elongation factor ELL2 modulate the ratio of secreted versus membrane-encoding Ighg2b transcripts in MPC11 plasmacytoma cell lines. hnRNPLL and ELL2 are both highly expressed in primary plasma cells relative to B cells, but hnRNPLL binds Ighg2b mRNA transcripts and promotes an increase in levels of the membrane-encoding Ighg2b isoform at the expense of the secreted Ighg2b isoform, whereas ELL2 counteracts this effect and drives Ig secretion by increasing the frequency of the secreted Ighg2b isoform. As in T cells, hnRNPLL also alters the splicing pattern of mRNA encoding the adhesion receptor CD44, promoting exon inclusion, and decreasing the overall level of CD44 expression. Further characterization of ELL2-dependent transcription by RNA-Seq revealed that ∼12% of transcripts expressed by plasma cells were differentially processed because of the activities of ELL2, including B-cell maturation antigen BCMA, a receptor with a defined role in plasma cell survival. Taken together, our data identify hnRNPLL and ELL2 as regulators of pre-mRNA processing in plasma cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22991471      PMCID: PMC3479602          DOI: 10.1073/pnas.1214414109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Consequences of increased CD45RA and RC isoforms for TCR signaling and peripheral T cell deficiency resulting from heterogeneous nuclear ribonucleoprotein L-like mutation.

Authors:  Zuopeng Wu; Adele L Yates; Gerard F Hoyne; Christopher C Goodnow
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

2.  Analysis and design of RNA sequencing experiments for identifying isoform regulation.

Authors:  Yarden Katz; Eric T Wang; Edoardo M Airoldi; Christopher B Burge
Journal:  Nat Methods       Date:  2010-11-07       Impact factor: 28.547

3.  A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.

Authors:  Jason Moffat; Dorre A Grueneberg; Xiaoping Yang; So Young Kim; Angela M Kloepfer; Gregory Hinkle; Bruno Piqani; Thomas M Eisenhaure; Biao Luo; Jennifer K Grenier; Anne E Carpenter; Shi Yin Foo; Sheila A Stewart; Brent R Stockwell; Nir Hacohen; William C Hahn; Eric S Lander; David M Sabatini; David E Root
Journal:  Cell       Date:  2006-03-24       Impact factor: 41.582

4.  An alternative splicing network links cell-cycle control to apoptosis.

Authors:  Michael J Moore; Qingqing Wang; Caleb J Kennedy; Pamela A Silver
Journal:  Cell       Date:  2010-08-12       Impact factor: 41.582

5.  Regulation of CD45 alternative splicing by heterogeneous ribonucleoprotein, hnRNPLL.

Authors:  Shalini Oberdoerffer; Luis Ferreira Moita; Daniel Neems; Rui P Freitas; Nir Hacohen; Anjana Rao
Journal:  Science       Date:  2008-07-10       Impact factor: 47.728

6.  IRF4 addiction in multiple myeloma.

Authors:  Arthur L Shaffer; N C Tolga Emre; Laurence Lamy; Vu N Ngo; George Wright; Wenming Xiao; John Powell; Sandeep Dave; Xin Yu; Hong Zhao; Yuxin Zeng; Bangzheng Chen; Joshua Epstein; Louis M Staudt
Journal:  Nature       Date:  2008-06-22       Impact factor: 49.962

7.  Memory T cell RNA rearrangement programmed by heterogeneous nuclear ribonucleoprotein hnRNPLL.

Authors:  Zuopeng Wu; Xinying Jia; Laura de la Cruz; Xun-Cheng Su; Bruz Marzolf; Pamela Troisch; Daniel Zak; Adam Hamilton; Belinda Whittle; Di Yu; Daniel Sheahan; Edward Bertram; Alan Aderem; Gottfried Otting; Christopher C Goodnow; Gerard F Hoyne
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

8.  Transcriptome-wide identification of RNA-binding protein and microRNA target sites by PAR-CLIP.

Authors:  Markus Hafner; Markus Landthaler; Lukas Burger; Mohsen Khorshid; Jean Hausser; Philipp Berninger; Andrea Rothballer; Manuel Ascano; Anna-Carina Jungkamp; Mathias Munschauer; Alexander Ulrich; Greg S Wardle; Scott Dewell; Mihaela Zavolan; Thomas Tuschl
Journal:  Cell       Date:  2010-04-02       Impact factor: 41.582

Review 9.  Mechanisms controlling production of membrane and secreted immunoglobulin during B cell development.

Authors:  Martha L Peterson
Journal:  Immunol Res       Date:  2007       Impact factor: 4.505

10.  Transcription elongation factor ELL2 directs immunoglobulin secretion in plasma cells by stimulating altered RNA processing.

Authors:  Kathleen Martincic; Serkan A Alkan; Alys Cheatle; Lisa Borghesi; Christine Milcarek
Journal:  Nat Immunol       Date:  2009-09-13       Impact factor: 25.606

View more
  22 in total

1.  Cytoplasmic poly(A)-binding protein 1 (PABPC1) interacts with the RNA-binding protein hnRNPLL and thereby regulates immunoglobulin secretion in plasma cells.

Authors:  Yuanzheng Peng; Juanjuan Yuan; Zhenchao Zhang; Xing Chang
Journal:  J Biol Chem       Date:  2017-06-13       Impact factor: 5.157

Review 2.  The generation of antibody-secreting plasma cells.

Authors:  Stephen L Nutt; Philip D Hodgkin; David M Tarlinton; Lynn M Corcoran
Journal:  Nat Rev Immunol       Date:  2015-02-20       Impact factor: 53.106

3.  RNA-binding protein hnRNPLL regulates mRNA splicing and stability during B-cell to plasma-cell differentiation.

Authors:  Xing Chang; Bin Li; Anjana Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

4.  Transcription elongation factor ELL2 drives Ig secretory-specific mRNA production and the unfolded protein response.

Authors:  Kyung Soo Park; Ian Bayles; Alec Szlachta-McGinn; Joshua Paul; Julie Boiko; Patricia Santos; June Liu; Zhou Wang; Lisa Borghesi; Christine Milcarek
Journal:  J Immunol       Date:  2014-09-19       Impact factor: 5.422

Review 5.  Genetic predisposition for multiple myeloma.

Authors:  Maroulio Pertesi; Molly Went; Markus Hansson; Kari Hemminki; Richard S Houlston; Björn Nilsson
Journal:  Leukemia       Date:  2020-01-08       Impact factor: 11.528

6.  Selective expression of the transcription elongation factor ELL3 in B cells prior to ELL2 drives proliferation and survival.

Authors:  Lou-Ella M M Alexander; January Watters; Jessica A Reusch; Michelle Maurin; Brook S Nepon-Sixt; Katerina Vrzalikova; Mark G Alexandrow; Paul G Murray; Kenneth L Wright
Journal:  Mol Immunol       Date:  2017-08-31       Impact factor: 4.407

7.  B Cell-Intrinsic Expression of the HuR RNA-Binding Protein Is Required for the T Cell-Dependent Immune Response In Vivo.

Authors:  Amy DeMicco; Martin S Naradikian; Vishal J Sindhava; Je-Hyun Yoon; Myriam Gorospe; Gerald B Wertheim; Michael P Cancro; Craig H Bassing
Journal:  J Immunol       Date:  2015-08-28       Impact factor: 5.422

8.  Multifunctional role of the transcription factor Blimp-1 in coordinating plasma cell differentiation.

Authors:  Martina Minnich; Hiromi Tagoh; Peter Bönelt; Elin Axelsson; Maria Fischer; Beatriz Cebolla; Alexander Tarakhovsky; Stephen L Nutt; Markus Jaritz; Meinrad Busslinger
Journal:  Nat Immunol       Date:  2016-01-18       Impact factor: 25.606

Review 9.  Coupling mRNA processing with transcription in time and space.

Authors:  David L Bentley
Journal:  Nat Rev Genet       Date:  2014-02-11       Impact factor: 53.242

Review 10.  The three as: Alternative splicing, alternative polyadenylation and their impact on apoptosis in immune function.

Authors:  Davia Blake; Kristen W Lynch
Journal:  Immunol Rev       Date:  2021-08-08       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.